{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:21:50Z","timestamp":1794255710767,"version":"4.9.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013529","name":"National Lottery Community Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ymgme.2026.110284","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:24:00Z","timestamp":1790688240000},"page":"110284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empowering children and young people with Erythropoietic Protoporphyria (EPP)\/X-linked Erythropoietic Protoporphyria (XLP): Outcomes of attending a disease-specific residential camp"],"prefix":"10.1016","volume":"149","author":[{"given":"Victoria A.","family":"McGuire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.110284_bb0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2133.1987.tb05904.x","article-title":"Erythropoietic protoporphyria: a study of its psychosocial aspects","volume":"116","author":"Rufener","year":"1987","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2133.2006.07472.x","article-title":"Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life","volume":"155","author":"Holme","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2133.2008.08581.x","article-title":"The quality of life of 790 patients with photodermatoses","volume":"159","author":"Jong","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2796.2010.02236.x","article-title":"Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics","volume":"269","author":"Wahlin","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2026.110284_bb0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/1346-8138.16690","article-title":"Erythropoietic protoporphyria in the Netherlands: clinical features, psychosocial impact and the effect of afamelanotide","volume":"50","author":"Wensink","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1210\/clinem\/dgae729","article-title":"The impact of minimal sunlight exposure on bone health: insights from a cohort study in erythropoietic protoporphyria","volume":"110","author":"Kluijver","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2026.110284_bb0035","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/1346-8138.17897","article-title":"The burden of Erythropoietic Protoporphyria (EPP): results from the EPP life impact and genetic health trajectory (LIGHT) study","volume":"52","author":"Naik","year":"2025","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0040","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/1346-8138.17348","article-title":"Quality of life in children with erythropoietic protoporphyria: a case\u2013control study","volume":"51","author":"Kluijver","year":"2024","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0045","series-title":"Burden of Illness and Unmet Needs in Patients With Erythropoietic Protoporphyria and X-Linked Protoporphyria: A Large US Nationwide Claims Analysis","author":"DerSarkissian","year":"2025"},{"key":"10.1016\/j.ymgme.2026.110284_bb0050","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/bjd.13598","article-title":"Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria","volume":"172","author":"Biolcati","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2026.110284_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-020-01505-6","article-title":"Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide-a three years observational study","volume":"15","author":"Barman-Aks\u00f6zen","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110284_bb0065","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/ced\/llaf306","article-title":"Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective","volume":"50","author":"Dawe","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0070","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2022.10.012","article-title":"Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and X-linked protoporphyria: a retrospective cohort study","volume":"88","author":"Ceresnie","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110284_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdin.2025.05.017","article-title":"Impact of delay in diagnosis in patients with erythropoietic protoporphyria: a cross-sectional survey study","author":"Tran","year":"2025","journal-title":"JAAD Int."},{"key":"10.1016\/j.ymgme.2026.110284_bb0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.childyouth.2018.04.046","article-title":"Benefits of disease-specific summer camps: results from quantitative and qualitative studies at Roundup River Ranch","volume":"89","author":"Meltzer","year":"2018","journal-title":"Child Youth Serv. Rev."},{"key":"10.1016\/j.ymgme.2026.110284_bb0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2019.01.023","article-title":"Psychosocial issues in erythropoietic protoporphyria - the perspective of parents, children, and young adults: a qualitative study","volume":"128","author":"Naik","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110284_bb0090","first-page":"A32.1","article-title":"04135 evaluating the impact of a family camp for erythropoietic protoporphyria (EPP) and other rare sun disorders","author":"Wheeden","year":"2024","journal-title":"BMJ"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:30:27Z","timestamp":1794252627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226005676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1096719226005676"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110284","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empowering children and young people with Erythropoietic Protoporphyria (EPP)\/X-linked Erythropoietic Protoporphyria (XLP): Outcomes of attending a disease-specific residential camp","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110284"}}